A detailed history of Bank Of America Corp transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 141,522 shares of RCUS stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
141,522
Previous 149,552 5.37%
Holding current value
$2.38 Million
Previous $2.82 Million 23.66%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.59 - $18.48 $117,157 - $148,394
-8,030 Reduced 5.37%
141,522 $2.16 Million
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $227,492 - $309,561
-15,340 Reduced 9.3%
149,552 $2.82 Million
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $310,622 - $454,022
-23,129 Reduced 12.3%
164,892 $3.15 Million
Q2 2023

Aug 14, 2023

SELL
$16.97 - $22.03 $16.3 Million - $21.2 Million
-961,197 Reduced 83.64%
188,021 $3.82 Million
Q1 2023

May 12, 2023

BUY
$15.96 - $23.15 $16.1 Million - $23.4 Million
1,010,207 Added 726.71%
1,149,218 $21 Million
Q4 2022

Feb 10, 2023

SELL
$19.7 - $35.71 $206,180 - $373,740
-10,466 Reduced 7.0%
139,011 $2.87 Million
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $1.57 Million - $2.03 Million
67,489 Added 82.32%
149,477 $3.91 Million
Q2 2022

Aug 12, 2022

SELL
$17.23 - $37.73 $955,799 - $2.09 Million
-55,473 Reduced 40.36%
81,988 $2.08 Million
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $1.16 Million - $1.67 Million
39,989 Added 41.03%
137,461 $4.34 Million
Q4 2021

Feb 08, 2022

BUY
$31.38 - $48.47 $903,806 - $1.4 Million
28,802 Added 41.94%
97,472 $3.95 Million
Q3 2021

Nov 15, 2021

BUY
$26.93 - $37.68 $858,609 - $1.2 Million
31,883 Added 86.67%
68,670 $2.39 Million
Q2 2021

Sep 13, 2021

BUY
$22.75 - $35.77 $836,904 - $1.32 Million
36,787 New
36,787 $1.01 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.21B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.